… cystic fibrosis, Leber's congenital amaurosis 10 and dystrophic epidermolysis bullosa, today announced a … Vienna, Austria. The presentation titled “IPRP UPLC Method Optimization for the Separation of Short- and Longmer … and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing …
… In addition, ProQR has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ordinary … The offering will be made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, … state or jurisdiction. About ProQR We are an innovative biopharmaceutical company engaged in the discovery and …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $7,500,000 of ordinary … proceeds from the offering to fund ongoing research and development activities and for working capital and other …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … offering, ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same … to fund its clinical trials, ongoing research and development activities and for working capital and other …
… PQ-110-001 Phase 1/2 trial PQ-110-001 is a first-in-human open-label trial that enrolled 5 children (age 6 - 17 years) … and 6 adults (≥ 18 years) who have LCA10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients … of visual function and retinal structure through ophthalmic endpoints, such as visual acuity (BCVA), mobility …
… NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through … addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of … proceeds from the offering to fund ongoing research and development activities and for working capital and other …
… lives through transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today … led to approx. 50% editing in liver of mice. New optimizations are being evaluated (not disclosed in the … prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing …
